Markets
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
52 week high
|
Strong Performer, Getting Expensive
2301.9000
-21.30
(
-0.92
%)
NSE
Feb 27, 2026
15:31 PM
New 52W High today
Volume:
955.4K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
07 Aug 2025
US FDA Approval
52 week high
2301.90
-0.92%
Result Update:Lupin
Buy:
Lupin Ltd.
by
Axis Direct
Target: 2400 | Upside : 4.3%
Target
Axis Direct
We recommend a BUY rating with a target price of Rs 2,500/share.
Lupin Ltd. is trading above all available SMAs
More from Lupin Ltd.
Recommended
Five Interesting Stocks Today - February 27, 2026
The Baseline |
27 Feb 2026, 05:51PM
Market closes lower, dragged down by losses in the banking, auto, and FMCG stocks
Trendlyne Marketwatch |
27 Feb 2026, 03:59PM
Lupin expects normalization by September quarter
|
17 Apr 2020